Compare OCUL & ARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCUL | ARR |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2014 | N/A |
| Metric | OCUL | ARR |
|---|---|---|
| Price | $9.11 | $17.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $22.56 | $18.17 |
| AVG Volume (30 Days) | ★ 6.1M | 3.8M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 16.36% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.65 |
| Revenue | $51,951,000.00 | ★ $116,798,000.00 |
| Revenue This Year | $20.43 | $296.22 |
| Revenue Next Year | $79.81 | $99.47 |
| P/E Ratio | ★ N/A | $27.06 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.79 | $13.18 |
| 52 Week High | $16.44 | $19.31 |
| Indicator | OCUL | ARR |
|---|---|---|
| Relative Strength Index (RSI) | 36.76 | 45.61 |
| Support Level | $8.36 | $17.03 |
| Resistance Level | $9.69 | $17.84 |
| Average True Range (ATR) | 0.67 | 0.39 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 27.37 | 37.00 |
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.